1. Bernard DS, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 2011; 29:2821–6.
Article
2. Davidoff AJ, Erten M, Shaffer T, Shoemaker JS, Zuckerman IH, Pandya N, et al. Out-of-pocket health care expenditure burden for medicare beneficiaries with cancer. Cancer. 2013; 119:1257–65.
Article
3. Guy GP Jr, Ekwueme DU, Yabroff KR, Dowling EC, Li C, Rodriguez JL, et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol. 2013; 31:3749–57.
Article
4. Bestvina CM, Zullig LL, Yousuf Zafar S. The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. Future Oncol. 2014; 10:2189–99.
Article
5. Witte J, Mehlis K, Surmann B, Lingnau R, Damm O, Greiner W, et al. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann Oncol. 2019; 30:1061–70.
Article
6. Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018; 68:153–65.
Article
7. Delgado-Guay M, Ferrer J, Rieber AG, Rhondali W, Tayjasanant S, Ochoa J, et al. Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients. Oncologist. 2015; 20:1092–8.
Article
8. de Souza JA, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, et al. The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer. 2014; 120:3245–53.
Article
9. de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araujo FS, Hlubocky FJ, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017; 123:476–84.
Article
10. Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol. 2015; 2:e408–16.
Article
11. Zafar SY, Pepercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013; 18:381–90.
Article
12. Allcott N, Dunham L, Levy D, Carr J, Stitzenberg K. Financial burden amongst cancer patients treated with curative intent surgery alone. Am J Surg. 2019; 218:452–6.
Article
13. Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 2017; 109:djw205.
Article
14. Benedict C, Fisher S, Schapira L, Chao S, Sackeyfio S, Sullivan T, et al. Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors. Psychooncology. 2021; 31:9–20.
Article
15. Mady LJ, Lyu L, Owoc MS, Peddada SD, Thomas TH, Sabik LM, et al. Understanding financial toxicity in head and neck cancer survivors. Oral Oncol. 2019; 95:187–93.
Article
16. Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, et al. Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract. 2014; 10:332–8.
Article
17. Gordon LG, Merollini KM, Lowe A, Chan RJ. A systematic review of financial toxicity among cancer survivors: we can’t pay the co-pay. Patient. 2017; 10:295–309.
Article
18. Jagsi R, Ward KC, Abrahamse PH, Wallner LP, Kurian AW, Hamilton AS, et al. Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer. Cancer. 2018; 124:3668–76.
Article
19. Ursachi G, Horodnic IA, Zait A. How reliable are measurement scales? External factors with indirect influence on reliability estimators. Proc Econ Finance. 2015; 20:679–86.
Article
20. Gorsuch RL. Exploratory factor analysis. Nesselroade JR, Cattell RB, editors. Handbook of multivariate experimental psychology. Boston, MA: Springer;1988. p. 231–58.
Article
21. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res. 2004; 13:863–8.
Article
22. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organization for Research and Treatment of Cancer;2001.
23. De Souza JA, Wroblewski K, Proussaloglou E, Nicholson L, Hantel A, Wang Y. Validation of a financial toxicity (FT) grading system. J Clin Oncol. 2017; 35(15_Suppl):6615.
Article
24. Rosenzweig M, West M, Matthews J, Stokan M, Yoojin Kook YK, Gallups S, et al. Financial toxicity among women with metastatic breast cancer. Oncol Nurs Forum. 2019; 46:83–91.
25. Chan RJ, Gordon L, Zafar SY, Miaskowski C. Financial toxicity and symptom burden: what is the big deal? Support Care Cancer. 2018; 26:1357–9.
Article
26. Smith GL, Lopez-Olivo MA, Advani PG, Ning MS, Geng Y, Giordano SH, et al. Financial burdens of cancer treatment: a systematic review of risk factors and outcomes. J Natl Compr Canc Netw. 2019; 17:1184–92.
Article
27. Azzani M, Roslani AC, Su TT. The perceived cancer-related financial hardship among patients and their families: a systematic review. Support Care Cancer. 2015; 23:889–98.
Article
28. de Souza JA, Kung S, O’Connor J, Yap BJ. Determinants of patient-centered financial stress in patients with locally advanced head and neck cancer. J Oncol Pract. 2017; 13:e310–8.
Article
29. Gupta D, Lis CG, Grutsch JF. Perceived cancer-related financial difficulty: implications for patient satisfaction with quality of life in advanced cancer. Support Care Cancer. 2007; 15:1051–6.
Article